Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
Saved in:
| Title: | Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. |
|---|---|
| Authors: | Geerlinks AV; Division Hematology and Oncology, Children's Hospital at London Health Sciences Centre, Western University, London, ON, Canada., Scull B; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX., Krupski C; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH., Fleischmann R; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX., Pulsipher MA; Division of Hematology and Oncology, Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT., Eapen M; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Connelly JA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN., Bollard CM; Center for Cancer and Immunology Research, Children's National Hospital and The George Washington University, Washington, DC., Pai SY; National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD., Duncan CN; Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA., Kean LS; Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA., Baker KS; Clinical Research Division, Fred Hutchinson Cancer Center and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA., Burroughs LM; Clinical Research Division, Fred Hutchinson Cancer Center and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA., Andolina JR; Department of Pediatrics, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, NY., Shenoy S; Division of Pediatric Hematology-Oncology, Washington University School of Medicine, St. Louis, MO., Roehrs P; Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA., Hanna R; Department of Pediatric Hematology and Oncology and BMT, Cleveland Clinic, Cleveland, OH., Talano JA; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI., Schultz KR; Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada., Stenger EO; Aflac Center and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA., Lin H; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX., Zoref-Lorenz A; Hematology Institute, Meir Medical Center, Kfar Saba, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH., McClain KL; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX., Jordan MB; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH., Man TK; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX., Allen CE; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX., Marsh RA; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH. |
| Source: | Blood advances [Blood Adv] 2023 Jul 25; Vol. 7 (14), pp. 3725-3734. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
